IINN
Inspira Technologies Oxy B.H.N. Ltd.·Healthcare
0.42
4.398%(+0.02)
Market ClosedLast Updated: — ET
52W L: $0.3452W H: $1.65
IINN NEWS
globenewswire.com
5d ago
Inspira Enters Quantum Computing Sector, Targeting a Critical Connectivity Bottleneck with Newly Acquired AME Platform
RA'ANANA, Israel, April 06, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (“Inspira” or the “Company”) today announced its entry into the quantum computing sector, targeting a critical connectivity bottleneck by directing its recently acquired additive manufactured electronics (“AME”) platform toward a new 3D architecture for systems operating in dilution cryostats.
globenewswire.com
5d ago
Inspira Technologies Announces Acquisition of the AME Platform from Nano Dimension
The transaction includes intellectual property , customer-related assets and commercial operations, positioning the Company for the next stage of its strategy
globenewswire.com
Mar 31
Inspira Technologies Terminates ATM and SEPA Equity Facilities to Prepare for Next Strategic Phase
RA'ANANA, Israel, March 31, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced the termination of its sales agreement with A.G.P./Alliance Global Partners, dated February 17, 2026, and its Standby Equity Purchase Agreement with YA II PN, Ltd, dated December 12, 2025.
globenewswire.com
Mar 26
Inspira Technologies Reports Full Year 2025 Financial Results and Provides Business Updates
Company Demonstrates Clinical Validation and Early Commercial Traction Toward 2026 Revenue Scale Company Demonstrates Clinical Validation and Early Commercial Traction Toward 2026 Revenue Scale
globenewswire.com
Feb 25
Inspira Receives Nasdaq Notification Regarding Minimum Market Value Deficiency
Ra'anana, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) (“Inspira Technologies” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that on February 19, 2026, it received written notice (the “Notice”) from The Nasdaq Stock Market (“Nasdaq”) advising the Company that it was not in compliance with Listing Rule 5550(b)(2) requiring companies listed on the Nasdaq Capital Market to maintain a minimum market value of publicly held shares of $35,000,000 (the “MVPHS Requirement”). Listing Rule 5550(b)(2) requires companies listed on the Nasdaq Capital Market to maintain a minimum market value of publicly held shares of $35,000,000. The Notice has no effect at this time on the listing of the Company's ordinary shares, which continues to trade on The Nasdaq Capital Market under the symbol “IINN.”
globenewswire.com
Feb 18
Inspira Expands U.S. Commercial Footprint: Deploys ART100 at a New Premier New York Academic Medical Center, Ranked Top 10 in New York State
RA'ANANA, Israel, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) (“Inspira Technologies” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced the deployment and initiation of a structured commercial evaluation of its U.S. Food and Drug Administration (“FDA”)-cleared INSPIRA™ ART100 system (the “ART100”) at a new and additional leading U.S. academic medical center.
